Augusto Grinspan

Suggest Changes
Learn More
BACKGROUND Fingolimod demonstrated superior efficacy compared with interferon β-1a intramuscular in relapsing multiple sclerosis. The impact of treatment history on fingolimod efficacy is unknown. (More)
BACKGROUND Fingolimod is a once-daily, oral sphingosine 1-phosphate receptor modulator approved for the treatment of relapsing multiple sclerosis. OBJECTIVE This post-hoc analysis of phase 3(More)